Suppr超能文献

意大利和欧洲的活菌治疗产品及其监管框架。

Live biotherapeutic products and their regulatory framework in Italy and Europe.

机构信息

Centro Nazionale per il Controllo dei Farmaci, Istituto Superiore di Sanità, Rome, Italy.

Agenzia Italiana del Farmaco, Rome, Italy.

出版信息

Ann Ist Super Sanita. 2023 Jan-Mar;59(1):56-67. doi: 10.4415/ANN_23_01_09.

Abstract

In Italy and Europe, live microorganisms-containing products meant to be used by vulnerable or sick people for preventing or curing a disease are defined as live biotherapeutic products and are regulated as biological drugs. As such, they must undergo extensive quality, safety and efficacy testing and evaluation before receiving a marketing authorization. This review describes the regulatory framework of live biotherapeutic products with special focus on the European Pharmacopoeia monograph 3053 that set mandatory requirements for this kind of medicines, including verification of the number of live microorganisms and absence of certain contamination indicator microorganisms. The other product categories that may contain live microorganisms are also described, with brief references to the overlaps possibly occurring between the different categories.

摘要

在意大利和欧洲,旨在供弱势群体或病人使用以预防或治疗疾病的含活微生物的产品被定义为活生物治疗产品,并按照生物药物进行监管。因此,在获得营销授权之前,它们必须经过广泛的质量、安全性和疗效测试和评估。本综述描述了活生物治疗产品的监管框架,特别关注欧洲药典 3053 专论,该专论为这类药物设定了强制性要求,包括验证活微生物数量和不存在某些污染指示微生物。还描述了可能含有活微生物的其他产品类别,并简要提及了不同类别之间可能存在的重叠。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验